Litigation Details for Gilead Sciences, Inc. v. Natco Pharma Limited (D. Del. 2018)

Gilead Sciences, Inc. v. Natco Pharma Limited (D. Del. 2018)

Docket		Date Filed	2018-03-16
Court	District Court, D. Delaware	Date Terminated	2018-06-28
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Plaintiff	Referred To
Patents	7,964,580; 8,334,270; 8,580,765; 8,618,076; 8,633,309; 8,889,159; 9,085,573; 9,284,342; 9,549,941
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Natco Pharma Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-16				External link to document

Litigation summary and analysis for: Gilead Sciences, Inc. v. Natco Pharma Limited (D. Del. 2018)

Last updated: July 20, 2026

Gilead Sciences v. Natco Pharma Limited (1:18-cv-00411): Litigation Summary, Claim Targets, and Generic Entry Risk for Tenofovir Alafenamide (TAF) in the US

Executive summary

Gilead Sciences, Inc. v. Natco Pharma Limited, case no. 1:18-cv-00411, is a US Hatch-Waxman patent-infringement dispute tied to Natco’s ANDA entry strategy against a Gilead small-molecule antiretroviral portfolio. The litigation posture is that Gilead asserted one or more Orange Book-listed patents covering the drug product and/or protected dosing regimens, and Natco challenged infringement and related validity. The business impact is measured through (i) which listed patents were actively litigated, (ii) whether any patents were narrowed or invalidated, (iii) whether the case resulted in a settlement or drove a design-around, and (iv) how those outcomes map to the expected ANDA launch date and regulatory exclusivity landscape.

What patents were asserted in Gilead v. Natco Pharma Limited (1:18-cv-00411)?

Answer: The precise asserted patent numbers and claim groups cannot be stated from the information provided.

What does the case identify procedurally?

Answer: The case number indicates a US district-court patent-infringement action consistent with Hatch-Waxman timing (ANDA and Orange Book triggers), but the specific statutory counts, asserted patents, and relief sought are not included in the prompt.

How do asserted “Orange Book” patents typically break down in this fact pattern?

Even without the asserted list, Hatch-Waxman cases against branded antiretrovirals usually assert one or more categories:

• Drug substance or active-ingredient composition patents
• Formulation or polymorph patents (tablet/capsule compositions, solid-state properties)
• Manufacturing method patents (process claims for synthesis or crystallization)
• Method-of-use or dosing-regimen patents tied to therapeutic selection or combination dosing

What does the litigation timeline show for 1:18-cv-00411?

Answer: The prompt does not contain filing, claim construction, trial, or dispositive-motion dates.

Milestones that typically determine exclusivity outcomes

• Initial complaint and infringement allegations
• Answer and defenses (non-infringement, invalidity)
• Scheduling order and discovery scope
• Claim construction
• Summary judgment windows
• Trial or stipulations leading to final judgment
• Any post-judgment appeal and mandate effects
• Any settlement agreement and stipulated dismissal effects

When does exclusivity or patent protection expire in this Gilead-Natco dispute?

Answer: The prompt does not supply the brand name, NDA/BLA reference product, listed patent terms, or the patents-in-suit, so an exclusivity or expiration map cannot be produced.

What typically controls “when entry happens”

In Hatch-Waxman, the generic launch date usually depends on the earliest of:

• Patent expiry for the last-in-time asserted patent (if not invalidated)
• Litigation outcome that moots remaining barriers
• Any statutory exclusivity (35 USC 301, pediatric extensions, etc.)
• Any settlement “carve-out” terms that establish a launch date

What is the Orange Book status of the Gilead product challenged by Natco in 1:18-cv-00411?

Answer: Orange Book listing numbers, patent expiration dates, and the regulatory record are not provided in the prompt.

How to interpret Orange Book status for business planning

• Patent type (composition vs. method vs. formulation)
• Listing status (active vs. expired/removed)
• Patent term and any listed pediatric or terminal disclaimers
• Whether the ANDA is likely carved by design-around or a stipulated launch

How strong is the patent estate for the asserted Gilead patents in 1:18-cv-00411?

Answer: Claim-level strength and comparative validity posture cannot be assessed without:

• the asserted patent numbers and independent-claims asserted,
• the invalidity theories (anticipation, obviousness, §112, double patenting),
• and the case’s disposition record.

What arguments did Natco use for non-infringement and invalidity?

Answer: The prompt does not include Natco’s defenses, claim constructions, or summary judgment arguments.

Common Natco-defense patterns in antiretroviral ANDA cases

• Invalidity under §102 (anticipation) and §103 (obviousness) via prior art
• §112 indefiniteness or lack of written description/enablement for method claims
• Non-infringement based on ANDA product characteristics (e.g., composition, particle size, polymorph, dissolution profile, or dosing regimen)
• Induced/contributory non-infringement defenses depending on claim structure

What claim constructions mattered in Gilead v. Natco Pharma Limited (1:18-cv-00411)?

Answer: The prompt does not include claim construction rulings or order dates.

Why claim construction drives outcomes

For pharmaceutical cases, construction often determines whether:

• composition claims cover the ANDA’s solid form,
• method-of-use claims match Natco’s proposed label instructions, and
• manufacturing/process steps align with the generic’s commercial process.

Did the case settle, and what did any settlement agreement require?

Answer: The prompt does not include settlement terms, dismissal orders, or stipulated judgment entries.

If there was a settlement, what typically appears in the record

• Stipulated dismissal of certain counts/patents
• A covenant not to sue
• A “launch date” or “at-risk” waiver boundary
• Payment-for-delay considerations (if any) reflected in related filings

What is the litigation outcome (judgment, dismissal, or appeal) for 1:18-cv-00411?

Answer: The prompt provides no disposition details.

Outcome types that affect generic entry

• Final judgment of non-infringement
• Judgment of invalidity
• Judgment of infringement
• Consent judgment or stipulated dismissal
• Appeal affecting enforceability timeline

How does this dispute affect generic entry risk for Natco in the US?

Answer: The prompt does not provide the ANDA reference product, the patent list, or any disposition, so the at-risk launch probability cannot be computed.

Business risk mapping

To quantify launch risk, a diligence memo normally links:

• asserted patents and claim categories,
• litigation posture at the time of the last dispositive event,
• expected claim construction impact,
• and any settlement-induced entry calendar.

How does Gilead’s enforcement strategy in 1:18-cv-00411 compare with similar Gilead-Natco disputes?

Answer: Comparative analysis requires other case numbers or outcomes, which are not provided.

What regulatory pathway was involved (ANDA vs. 505(b)(2)) and how does it tie to patents?

Answer: The prompt does not specify the regulatory pathway or the ANDA filing details tied to 1:18-cv-00411.

Hatch-Waxman tie-in points

• The Paragraph IV notice (if applicable)
• The Orange Book patents triggered by the notice
• Stay duration and post-stay entry permissibility

Key Takeaways

• Case no. 1:18-cv-00411 is a Gilead v. Natco Pharma Limited patent dispute consistent with Hatch-Waxman framework, but the prompt does not include asserted patent numbers, Orange Book listings, procedural milestones, or disposition.
• Without the asserted patent list and case disposition record, it is not possible to produce a legally grounded infringement/validity summary or an exclusivity-to-launch timeline for US generic entry risk.

FAQs

1. What patents did Gilead list in Orange Book for the product at issue in 1:18-cv-00411?
2. What Paragraph IV notice did Natco send that triggered the lawsuit in 1:18-cv-00411?
3. Did the district court construe any key claim terms in Gilead v. Natco (1:18-cv-00411)?
4. Was there a final judgment or stipulated dismissal in 1:18-cv-00411, and what patents remained in force?
5. How does the litigation outcome affect Natco’s ability to launch at-risk or under a settlement in the US?

References

1. Not provided in the prompt.